In total, 610 patients were randomized to receive degarelix (administered via subcutaneous injection) at a starting dose of 240 mg, followed by maintenance doses of 80 mg/month (n = 207 ...

[11] In the current study, degarelix achieved a complete response in 20 % of patients after 1 year and 19 % after 2 years; although this value rose to 35 % at 3 years, patient numbers at this time ...